Introduction {#S0001}
============

Physical activity and sedentary behavior both contribute to health outcomes, such that high mortality rates are observed in people who have low levels of physical activity and high sedentary times.[@CIT0001]--[@CIT0003] There has been increasing recognition of the interrelationship between sitting time and physical activity, such that the 2018 Physical Activity Guidelines for Americans recommend that adults, and in particular older adults, "move more and sit less throughout the day."[@CIT0004] Despite this, the effect of reducing sedentary time on health outcomes has not been fully investigated.

Sedentary behavior is defined as energy expenditure of ≤1.5 metabolic equivalents (METs) while awake and in a sitting or reclining posture.[@CIT0005],[@CIT0006] People have a better health profile when they have less sedentary time.[@CIT0007] For example, increased sedentary time correlates with cardiac event risk and mortality, while less time spent sedentary is associated with higher levels of high-density lipoprotein cholesterol.[@CIT0008],[@CIT0009] Additionally, people with diabetes mellitus who have an increased number of breaks in their sedentary time have beneficial reductions in their waist circumferences and plasma glucose levels.[@CIT0010]

Patients with COPD are markedly inactive because of airflow limitation.[@CIT0011] When people with COPD engage in activity, it is characterized by shortness of breath because of lung hyperinflation.[@CIT0012]--[@CIT0014] However, in patients with COPD, the risk of death increases not only because of a reduced level of physical activity, but also because of an increased amount of sedentary time. It has previously been shown that patients with COPD have less standing time and prolonged sedentary time.[@CIT0011] Further, a recently published study showed that increased sedentary time is associated with a higher risk of death independent of physical activity among patients with COPD.[@CIT0015],[@CIT0016] Therefore, it is important to reduce sedentary behavior and increase physical activity in patients with COPD, as research shows that increasing low-intensity, rather than high-intensity, activities reduces the risk of hospitalization for these patients.[@CIT0017]

There are many factors that can affect the physical activity of patients with COPD, including comorbidities, physiological factors, and psychological factors.[@CIT0018] Currently, drug intervention trials assess patients with COPD based on patients' physical activity levels rather than sedentary behavior. This is primarily because a physical activity assessment is considered to be more objective and reliable than a questionnaire.[@CIT0019] However, physical activity data from an accelerometer require several variables to be prespecified to ensure high levels of reproducibility and sensitivity. This includes prespecification of observation intervals and a minimum number of days to obtain data, as well as exclusion of 1) non wear time, 2) periods when device malfunction interrupts recording of data, 3) periods when external factors such as bad weather prevent activity, and 4) sleeping time, especially for the evaluation of sedentary time.

It is now known that even if people are physically active, there are serious metabolic consequences associated with prolonged sedentary behavior.[@CIT0020]--[@CIT0022] Therefore, targeting sedentary behavior in patients with COPD is an important consideration when evaluating how drug interventions work. Tiotropium is a widely used maintenance treatment for COPD. The VESUTO^®^ study was designed to investigate the efficacy of a fixed dose of tiotropium in combination with olodaterol versus tiotropium monotherapy by assessing lung hyperinflation and exercise capacity in Japanese patients with COPD.[@CIT0023],[@CIT0024] To our knowledge, there are no reports presently available that describe bronchodilator use with reductions in sedentary duration.

Using the activity data of patients enrolled in the VESUTO study, we performed a post hoc analysis to investigate whether tiotropium/olodaterol combination therapy reduces sedentary time and increases activity levels compared with tiotropium monotherapy. Additionally, we investigated factors associated with reduced sedentary time and increased activity levels.

Patients and methods {#S0002}
====================

Patients {#S0002-S2001}
--------

The inclusion and exclusion criteria are described in full in the primary report.[@CIT0024] In brief, patients were included if they were aged ≥40 years, diagnosed with COPD, and had a GOLD grade II--IV. Exclusion criteria included the presence of current documented bronchial asthma or a clinically significant abnormality in hematology, blood chemistry, or urinalysis parameters.

Institutional review boards at each participating site approved the study (see Table S1), and all patients provided written informed consent. The study was conducted in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice, the Declaration of Helsinki, the Japanese Good Clinical Practice regulations (Ministry of Health and Welfare Ordinance No. 28, March 27, 1997) and all relevant local regulatory, legal, and ethical requirements.

Study design and treatment {#S0002-S2002}
--------------------------

This was a post hoc analysis of the VESUTO study, where tiotropium/olodaterol combination therapy was compared with tiotropium monotherapy for its ability to improve inspiratory capacity (IC) and physical activity levels in patients with COPD.[@CIT0024] The VESUTO study was a multicenter, randomized, double-blind, active-controlled, two-way crossover trial as described previously.[@CIT0023] All patients received long-acting muscarinic antagonist (LAMA) or long-acting β~2~-agonist (LABA) monotherapy for at least 5 weeks before randomization. After randomization, patients received once-daily tiotropium/olodaterol 5/5 μg inhalation solution (2.5/2.5 μg per actuation) for 6 weeks, followed by tiotropium 5 μg inhalation solution (2.5 μg per actuation) for 6 weeks, or vice versa. All inhalation solutions were administered via a RESPIMAT^®^ inhaler (Boehringer Ingelheim, Ingelheim, Germany).

Analysis of effects on physical activity durations {#S0002-S2003}
--------------------------------------------------

During the VESUTO study, patients were provided with a three-axis accelerometer (Active style PRO HJA-750C, HJA-750C; OMRON, Kyoto, Japan) 2 weeks before the end of the 6-week study period to measure physical activity. Patients were asked to wear the accelerometer on their waist, all day, except when bathing or engaging in water-based activities. Patients were not able to view data on the accelerometer screen. As previously defined, periods of sedentary time were categorized as an energy expenditure of 1.0--1.5 METs, whereas periods of physical activity performed at more than light (ie, light, moderate, or vigorous) and more than moderate (ie, moderate or vigorous) intensities were categorized as ≥2.0 METs and ≥3.0 METs, respectively.[@CIT0006],[@CIT0018],[@CIT0025]

The duration of each MET category was calculated using raw data obtained from each patient. To enhance the sensitivity of these assessments and because sleeping time was not collected in all patients, data were collected from 8 [AM]{.smallcaps} to 9 [PM]{.smallcaps} to include the time when patients were awake and exclude the time spent sleeping, in keeping with a previous report.[@CIT0011] Furthermore, to obtain more reproducible data, and as in a previous study that assessed physical activity levels in patients with COPD,[@CIT0019] activity data were excluded if the measurement device was worn for \<10 hrs per day, and on rainy days, which have been shown to deter outdoor activity.[@CIT0019],[@CIT0026],[@CIT0027] Finally, at least 3 valid days were required (ie, days with ≥10 hrs' wearing time and non rainy days). Wearing time was defined as periods with \>1.0 MET. Rainy days were excluded based on patients' diaries. Therefore, activity data were excluded if there were fewer than 3 valid days during the study period.[@CIT0019]

Subgroup analyses {#S0002-S2004}
-----------------

The outcome variable was the mean difference between treatments (ie, tiotropium/olodaterol relative to tiotropium) in the change from baseline of the duration of each MET category. Improvement was defined as a greater decrease from baseline in the duration of 1.0--1.5 METs, or a greater increase from baseline in the duration of ≥2.0 METs or ≥3.0 METs, with tiotropium/olodaterol than with tiotropium. Subgroup analyses were performed to assess whether there were any differences in improvements in the duration of each MET category according to baseline characteristics, such as age; body mass index (BMI); lung function (FEV~1~, IC, FVC); GOLD grade; mMRC) score; St George's Respiratory Questionnaire (SGRQ) total score, each domain activity, impact, and symptom score; and baseline duration of each MET category (1.0--1.5 METs, ≥2.0 METs, and ≥3.0 METs). Furthermore, we investigated the relationship between improvements in lung function and improvements in the duration of each MET category.

Additionally, the data of patients with FEV~1~ response (FEV~1~ improvement ≥100 mL) and those without FEV~1~ response (FEV~1~ improvement \<100 mL) were analyzed in terms of improvement in the duration of each MET category.

Statistical methods {#S0002-S2005}
-------------------

The sample size calculation and preplanned analytical populations are described in the design paper.[@CIT0023] Statistical analyses to evaluate treatment effect were conducted using a mixed-effects model repeated measures (SAS/STAT^®^ 13.1 MIXED procedure; SAS Institute Inc., Cary, NC, USA) approach with treatment and period as categorical fixed effects, study baseline (Visit 2) as a covariate, and patient as a random effect. Univariable and multivariable linear regression analyses were performed to explore the baseline factors associated with treatment response. As an appropriate clinical model regarding the relationship between baseline factors and improvement of physical activity is lacking, we included baseline factors, except for highly correlated factors such as those of lung function, in the multivariable regression model as explanatory variables. Factors were included as continuous variables, except for age (\<65, 65--75, or ≥75 years, as per a previous report[@CIT0028]), BMI (\<18.5, 18.5--25, or ≥25 kg/m^2^), GOLD grade (II or III/IV), and mMRC score (1 or ≥2). In addition, responder rate based on the duration of each MET category was calculated between groups with and without differences ≥100 mL in FEV~1~ between tiotropium/olodaterol and tiotropium alone. Differences between groups were judged to be statistically significant at *p*\<0.05. However, as this is a post hoc analysis, the *p*-values reported should be considered nominal.

Results {#S0003}
=======

Patients {#S0003-S2001}
--------

The disposition of patients is shown in [Figure 1](#F0001){ref-type="fig"}. Of the 182 patients enrolled, 52 had fewer than 3 valid days and were excluded, resulting in 131 who satisfied the conditions for the present analysis. Two patients withdrew informed consent after experiencing adverse events (unexpected worsening of the disease under study in both cases), while the remaining 129 patients completed the study. Baseline demographics and clinical characteristics are shown in [Table 1](#T0001){ref-type="table"}.Table 1Patient demographics and baseline disease characteristics (n=131)CharacteristicValueMean age, years (SD)71.6 (6.6)Sex, male (%)112 (85.5)Mean body mass index, kg/m^2^ (SD)21.7 (4.0)Mean duration of COPD, years (SD)5.5 (4.6)Smoker status, n (%) Current22 (16.8) Ex-smoker109 (83.2)Pulmonary function data (post bronchodilator), mean (SD) IC (L)1.81 (0.52) FEV~1~ (L)1.22 (0.41) FEV~1~ (% predicted)52.57 (15.00) FVC (L)2.96 (0.71) FEV~1~/FVC (%), mean (SD)41.70 (10.74)FEV~1~ category, n (%) GOLD grade II (50% to \<80%)73 (55.7) GOLD grade III (30% to \<50%)46 (35.1) GOLD grade IV (\<30%)12 (9.2)mMRC dyspnea score, mean (SD)1.9 (0.8)Mean daily physical activity duration (mins), mean (SD)^a^ Duration of 1.0--1.5 METs408.4 (90.0) Duration of ≥2.0 METs177.3 (64.4) Duration of ≥3.0 METs44.2 (24.7)[^1][^2] Figure 1Patient disposition.**Note:** ^a^Reasons for valid days included days with ≥10 hrs' wearing time and non-rainy days.

For tiotropium/olodaterol combination therapy and tiotropium monotherapy, the mean (SD) total wear time between 8 [AM]{.smallcaps} and 9 [PM]{.smallcaps} was 665.6 (51.2) mins and 668.4 (52.8) mins, respectively. In addition, the mean (SD) number of valid days was 11.23 (3.14) and 11.47 (2.89); the mean (SD) number of rainy days was 1.24 (2.09) and 1.12 (1.88); and the mean number of days with less than 10 hrs' wear time was 1.46 (2.43) and 1.35 (2.21), respectively.

Outcomes of analysis on physical activity durations {#S0003-S2002}
---------------------------------------------------

Tiotropium/olodaterol combination therapy significantly reduced the duration of 1.0--1.5 METs by 8.64 mins more than with tiotropium monotherapy (95% CI −16.88 to −0.40; *p*=0.040) ([Figure 2A](#F0002){ref-type="fig"}). In addition, tiotropium/olodaterol combination therapy significantly increased the duration of ≥2.0 METs by 6.51 mins (95% CI 1.17 to 11.85; *p*=0.017) and ≥3.0 METs by 2.60 mins (95% CI 0.70 to 4.49; *p*=0.008) more than with tiotropium monotherapy ([Figure 2B](#F0002){ref-type="fig"} and [C](#F0002){ref-type="fig"}).Figure 2Activity durations for 1.0--1.5 METs (**A**), ≥2.0 METs (**B**), and ≥3.0 METs (**C**).**Notes:** Error bars represent SEs.**Abbreviations:** Adj., adjusted; METs, metabolic equivalents; Tio, tiotropium; T+O, tiotropium/olodaterol.

Subgroup analysis outcomes {#S0003-S2003}
--------------------------

In the subgroup analysis of the relationship between patient characteristics and improvement in duration of each MET category, it was shown that, compared with tiotropium alone, tiotropium/olodaterol combination therapy significantly improved (reduced) the duration of 1.0--1.5 METs in subgroups with the following baseline characteristics: IC values greater than or equal to the median, FVC values greater than or equal to the median, age ≥75 years, BMI ≥25 kg/m^2^, SGRQ scores less than the median, and baseline duration of ≥3.0 METs greater than or equal to the median ([Figure 3A](#F0003){ref-type="fig"}). Moreover, improvements in the duration of ≥2.0 METs ([Figure 3B](#F0003){ref-type="fig"}) and the duration of ≥3.0 METs ([Figure 3C](#F0003){ref-type="fig"}) tended to be greater with tiotropium/olodaterol than with tiotropium in patients aged ≥75 years (significant for duration of ≥2.0 METs only); in patients with BMI ≥25 kg/m^2^ (significant for duration of ≥3.0 METs only); in those with the baseline lung function parameters IC, FEV~1~, and FVC values greater than or equal to the median; in those with GOLD grade II, mMRC=1, and SGRQ scores less than the median value; and in those with baseline duration of 1.0--1.5 METs less than the median, baseline duration of ≥2.0 METs greater than or equal to the median, and baseline duration of ≥3.0 METs greater than or equal to the median. Similar tendencies were also observed when the percent change from baseline in the duration of each MET category was examined (Figure S1).Figure 3The effect of tiotropium/olodaterol combination therapy versus tiotropium monotherapy in time spent on 1.0--1.5 METs (**A**), ≥2.0 METs (**B**), and ≥3.0 METs (**C**) activity levels (change from baseline) by subgroups defined by baseline factors.**Abbreviations:** BMI, body mass index; IC, inspiratory capacity; METs, metabolic equivalents; SGRQ, St George's Respiratory Questionnaire; Tio, tiotropium; T+O, tiotropium/olodaterol.

Univariable and multivariable analyses were conducted to investigate associations of baseline age, BMI, IC, FEV~1~, FVC, GOLD, mMRC, SGRQ, and duration of each MET category with patient outcomes. There was an association between baseline SGRQ total score and SGRQ activity domain and an improvement in duration of 1.0--1.5 METs in the univariable analysis; similar results were observed for the SGRQ activity domain in the multivariable analysis ([Table 2A](#T0002){ref-type="table"}). The univariable analysis showed that FEV~1~, FVC, and SGRQ total score, activity domain, and impact domain were associated with improvements in the duration of ≥2.0 METs. However, statistical significance was not observed in the multivariable analysis ([Table 2B](#T0002){ref-type="table"}). Regarding the duration of ≥3.0 METs, the univariable analysis showed that FEV~1~, FVC, and SGRQ activity domains were associated with improvements, and the multivariable analysis showed that BMI, FEV~1~, and SGRQ activity domains were associated with improvements in this activity level ([Table 2C](#T0002){ref-type="table"}).Table 2Baseline factors associated with improvements in physical activitiesBaseline factorUnivariable analysisMultivariable analysisCategoryEstimate95% CI*p*-valueEstimate95% CI*p*-valueLowerUpperLowerUpper**A. 1.0--1.5 MET activity**Age, years\<650.00\--0.2990.00\--0.400≥65, \<75--11.57--38.0814.94--10.69--39.2917.92≥75--21.41--49.857.04--20.80--53.1411.53Body mass index, kg/m^2^\<18.50.0010\--0.1220.00\--0.051≥18.5, \<25.0--6.26--26.4213.900.25--22.0822.57≥25.0--27.34--54.55--0.14--29.99--59.84--0.15IC (L)Continuous--7.43--23.248.3700.353\-\-\--FEV~1~ (L)Continuous--9.95--29.189.280.3071.08--21.2023.350.924FVC (L)Continuous--10.66--21.890.560.063\-\-\--GOLD gradeII--0.40--17.1216.330.963\-\-\--III/IV0.00\-\-\-\-\--mMRC dyspnea score1--1.25--18.5716.060.8868.03--10.7126.770.397≥20.00\--0.00\--SGRQ totalContinuous0.560.001.120.050\-\-\--SGRQ activityContinuous0.520.040.990.0340.650.041.260.037SGRQ impactContinuous0.50--0.021.030.061\-\-\--SGRQ symptomContinuous0.14--0.280.560.511\-\-\--Duration of 1.0--1.5 METsContinuous0.02--0.070.110.670--0.01--0.200.190.941Duration of ≥2.0 METsContinuous--0.02--0.140.110.782--0.07--0.430.280.682Duration of ≥3.0 METsContinuous--0.04--0.370.300.8280.23--0.420.890.486**B. ≥2.0 MET activity**Age, years\<650.00\--0.3720.00\--0.404≥65, \<757.91--9.5825.396.91--11.9625.79≥7513.10--5.6731.8713.61--7.7234.94Body mass index, kg/m^2^\<18.50.00\--0.2790.00\--0.131≥18.5, \<25.00.33--13.0513.70--6.76--21.497.97≥25.012.50--5.5530.549.33--10.3629.03IC (L)Continuous7.19--3.1617.550.172\-\-\--FEV~1~ (L)Continuous12.590.1025.090.0488.08--6.6222.780.278FVC (L)Continuous9.492.1916.780.011\-\-\--GOLD gradeII5.57--5.3916.530.316\-\-\--III/IV0.00\-\-\-\-\--mMRC dyspnea score14.96--6.4016.320.389--0.05--12.4212.310.993≥20.00\--0.00\--SGRQ totalContinuous--0.42--0.78--0.050.026\-\-\--SGRQ activityContinuous--0.36--0.67--0.050.024--0.33--0.730.080.112SGRQ impactContinuous--0.37--0.72--0.030.034\-\-\--SGRQ symptomContinuous--0.15--0.430.130.291--0.03--0.160.090.606Duration of 1.0--1.5 METsContinuous--0.01--0.070.050.727\-\-\--Duration of ≥2.0 METsContinuous0.00--0.080.080.977--0.04--0.270.200.756Duration of ≥3.0 METsContinuous0.02--0.200.240.890--0.09--0.520.340.679**C. ≥3.0 MET activity**Age, years\<650.00\--0.8690.00\--0.569≥65, \<750.98--5.237.18--0.07--6.416.27≥751.72--4.948.382.25--4.929.41Body mass index, kg/m^2^\<18.50.00\--0.0600.00\--0.011≥18.5, \<25.0--3.34--7.991.30--5.34--10.29--0.39≥25.02.65--3.618.921.80--4.828.41IC (L)Continuous2.99--0.646.630.106\-\-\--FEV~1~ (L)Continuous6.482.1710.790.0045.060.1210.000.045FVC (L)Continuous3.751.206.300.004\-\-\--GOLD gradeII3.48--0.357.300.074\-\-\--III/IV0.00\-\-\-\-\--mMRC dyspnea score11.13--2.885.140.578--1.26--5.412.900.550≥20.00\--0.00\--SGRQ totalContinuous--0.13--0.260.000.053\-\-\--SGRQ activityContinuous--0.15--0.26--0.040.007--0.14--0.28--0.010.039SGRQ impactContinuous--0.09--0.220.030.134\-\-\--SGRQ symptomContinuous--0.03--0.130.070.5370.02--0.020.060.346Duration of 1.0--1.5 METsContinuous--0.00--0.020.020.919\-\-\--Duration of ≥2.0 METsContinuous0.01--0.020.040.4980.02--0.060.100.623Duration of ≥3.0 METsContinuous0.05--0.030.120.2520.00--0.140.150.998[^3]

We then investigated whether improvements in lung function parameters achieved during treatment were associated with improved duration of each MET category. Patients with an improvement in FEV~1~ that was greater than or equal to the median FEV~1~ after treatment showed reductions in the duration of 1.0--1.5 METs ([Figure 4A](#F0004){ref-type="fig"}; −12.65 mins \[95% CI −24.10 to −1.21\]) and increases in the durations of ≥2.0 METs ([Figure 4B](#F0004){ref-type="fig"}; 8.92 mins \[95% CI 1.13 to 16.71\]) and ≥3.0 METs ([Figure 4C](#F0004){ref-type="fig"}: 2.93 mins \[95% CI 0.11 to 5.76\]). Similar tendencies were observed when the percent change from baseline duration of each MET category was examined (Figure S2).Figure 4The relationship between improvements in lung function during treatment and duration of 1.0--1.5 MET (**A**), ≥2.0 MET (**B**), and ≥3.0 MET (**C**) activity levels (change from baseline).**Abbreviations:** IC, inspiratory capacity; METs, metabolic equivalents; SGRQ, St George's Respiratory Questionnaire; Tio, tiotropium; T+O, tiotropium/olodaterol.

Additionally, it was shown that patients who had FEV~1~ improvements ≥100 mL (FEV~1~ responders) tended to experience greater improvements in the duration of each MET category than FEV~1~ non responders (ΔFEV~1~\<100 mL) (Figure S3).

Discussion {#S0004}
==========

The VESUTO study initially showed that tiotropium/olodaterol combination therapy reduced hyperinflation, potentially improved exercise capacity, and resulted in mild-to-moderate increases in the duration of active behavior, compared with tiotropium monotherapy.[@CIT0024] This post hoc analysis showed that tiotropium/olodaterol combination therapy statistically significantly reduced the duration of 1.0--1.5 METs (sedentary time) by 8.64 mins and increased the durations of ≥2.0 METs and ≥3.0 MET physical activity by 6.51 mins and 2.60 mins, respectively. To our knowledge, this is the first study to provide evidence of a significant reduction in sedentary time in patients with COPD who are administered LAMA/LABA compared to LAMA alone, although the clinical meaning of this change is unclear. These findings may be important because sedentary time has been shown to increase the risk of mortality independent of the duration of active behavior in patients with COPD.[@CIT0015],[@CIT0016] Moreover, increasing the duration of low-intensity activity, rather than high-intensity activity, contributes to a lower risk of hospitalization in patients with COPD.[@CIT0017]

In this study, the subgroup analyses showed that compared with tiotropium alone, tiotropium/olodaterol combination therapy decreased sedentary time and increased physical activity in patients with better baseline lung function, milder dyspnea, and higher levels of physical activity at baseline, and in patients who were older and overweight. In addition, sedentary time was shorter and the duration of physical activity was longer in subjects aged ≥75 years, which may have been due to patients aged ≥75 years having higher baseline activity levels. This is supported by findings from the Japan National Health and Nutrition Survey from 2016, which showed that self-reported regular exercise habits were higher in patients aged ≥70 years than in subjects aged between 60 and 70 years.[@CIT0029] Overall, our findings suggest that patients with COPD and milder airflow limitations, milder symptoms, and a higher physical activity level at baseline may show greater improvements in physical activity with tiotropium/olodaterol combination therapy compared with tiotropium monotherapy. Although further trials are required to determine the effect of these factors, these findings are consistent with previous findings and suggest that early treatment with tiotropium/olodaterol combination therapy in patients with less severe disease could contribute to enhanced physical activity levels.[@CIT0030],[@CIT0031]

The multivariable regression analysis showed no statistically significant associations between baseline characteristics and sedentary improvement. However, baseline FEV~1~ was associated with improvements in ≥3.0 METs. This suggests that lifestyle and socio environmental factors, rather than baseline lung function, influence sedentary time, whereas activity ≥3.0 METs (moderate-to-vigorous intensity) is more influenced by lung function. This is consistent with a previous observational study in which a change in the high intensity of physical activity after bronchodilator use correlated with baseline lung function.[@CIT0030]

Subsequently, we investigated whether improvements in lung function after 6 weeks of treatment were associated with improvements in physical activity. There was a tendency for decreased sedentary times and increased physical activity durations in patients who had greater improvements in lung function, such as FEV~1~. This suggests that the improved airflow limitation observed with tiotropium/olodaterol combination therapy may contribute to improvements in patients' physical activity.[@CIT0032],[@CIT0033] To further support this point, we also observed that there was a tendency for improved physical activity among patients who showed improvements of \>100 mL in FEV~1~.

When assessing physical activity levels, it is important to extract only valid data to ensure enhanced reliability/sensitivity. In particular, sleeping time and non wear time have a greater effect on the evaluation of sedentary time than on the evaluation of active behavior. Therefore, to ensure valid data for assessment of sedentary time, we used stricter criteria than in our previous report. Specifically, we aimed to extract data when patients were awake (ie, between 8 [AM]{.smallcaps} and 9 [PM),]{.smallcaps} as the exclusion of sleeping time is critical for accurately evaluating sedentary time. We also excluded days when patients wore the activity measurement device \<10 hrs, and when it was raining (which can affect physical activity). Importantly, we included data only from patients who had ≥3 valid days.[@CIT0034] It has been previously reported that seasons and possibly also the weather can significantly affect physical activity levels.[@CIT0035],[@CIT0036] Therefore, although we excluded data from rainy days, it is possible that seasonal differences in physical activity may have occurred during the VESUTO study, which enrolled patients throughout an entire year.[@CIT0024] Overall, the conditions used to define valid data were stricter than in our previous report.

We used the three-axis accelerometer HJA-750C in which 3 different algorithms were employed to evaluate sedentary, light-intensity, and moderate-intensity activity.[@CIT0037] This monitor is comparable with the already validated DynaPort Move Monitor (McRoberts, The Hague, The Netherlands) and the Actimaker (Panasonic, Osaka, Japan).[@CIT0034] Therefore, the HJA-750C model was considered to be an appropriate measure for analyzing both active and sedentary time in this study.

Although an increase of 1000 steps in daily walking can reduce the risk of hospitalization by 20%,[@CIT0017] the findings from our study suggest that it is equally important to reduce time spent in inactive postures such as sitting. The American College of Sports Medicine recommends either ≥30 mins of moderate aerobic exercise 5 days per week or ≥20 mins of vigorous exercise 3 days per week[@CIT0038] and, although the 2018 Physical Activity Guidelines for Americans acknowledge the risks of excessive sedentary time, there are no quantitative guidelines currently available for sitting time or recommendations for sitting time durations throughout the day.[@CIT0004]

Our findings showed that sedentary time decreased with tiotropium/olodaterol combination therapy. However, it remains unclear whether this indicates a clinically significant improvement with drug treatment and whether this improvement can contribute to better clinical outcomes. Therefore, further studies are required to determine the clinical relevance of improvements in sedentary time with tiotropium/olodaterol combination therapy. It is expected that, in addition to drug interventions, further reductions in sedentary time and improved levels of physical activity could be achieved with patient education, rehabilitation, and behavioral change programs.[@CIT0018]

Limitations {#S0004-S2001}
-----------

This study is limited by the post hoc nature of the analyses of a study that was not designed to evaluate sedentary time, the use of exploratory analyses that were not adjusted for multiplicity, the relatively short duration of the study, and the inclusion of only Japanese patients with COPD, which limits the generalizability to other populations. In this study, patients were asked to wear their accelerometers all day for 14 days, and 51 of 182 patients were excluded from the analyses because they had fewer than 3 valid days (ie, ≥10 hrs' wearing time and non rainy days). Guidelines for extracting data for the assessment of physical activity levels were not stipulated, and non wearing time and lying down resting periods are not clearly distinguishable, which is a limitation inherent in all activity monitors. Therefore, it is possible that patients may have slept within the data collection period of 8 [AM]{.smallcaps} to 9 [PM]{.smallcaps}. In addition, lung function is not the only contributor to the physically inactive lifestyle of many individuals with COPD, and physical activity can be affected by many other factors including comorbidities, physiological factors, and psychological well-being.[@CIT0018] However, the crossover design of this study would, in part, control for any potential differences in these contributing factors between groups.

Conclusion {#S0005}
==========

This post hoc analysis of the VESUTO study showed that tiotropium/olodaterol combination therapy reduced the sedentary time (1.0--1.5 METs) and improved the duration of more than light (≥2.0 METs) and more than moderate (≥3.0 METs) activity compared with tiotropium monotherapy. The limitations of this research should be taken into account when designing future studies.
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[^1]: **Note:** ^a^Measured over 14 days prior to baseline.

[^2]: **Abbreviations:** IC, inspiratory capacity; METs, metabolic equivalents.

[^3]: **Abbreviations:** IC, inspiratory capacity; METs, metabolic equivalents; SGRQ, St George's Respiratory Questionnaire.
